GHRS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GH

Mkt Cap

$1.25B

Volume

142.58K

Next Earnings

November 5th

Loading chart

GH

GHRSGH Research PLC Ordinary Shares

GHRS

Pay with—

Available Balance0.00

GH

Mkt Cap

$1.25B

Volume

142.58K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS TreatmentsFive psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.Benzinga · Feb 27, 2026

Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED)U.S. stock futures rose on Monday as major indices opened the first full trading week of 2026 higher. Following the U.S. strike on Venezuela and removal of President Maduro, crude oil prices fluctuated around $57.29 per barrel. Several stocks gained attention: Vertiv Holdings jumped on an upgrade, GH Research soared on FDA update news, Nukkleus rose after acquiring Israeli defense software, Ironwood advanced on positive FY26 guidance, and Brand Engagement Network climbed on a new vendor agreement. JPMorgan's outlook suggests continued but challenged strength in U.S. equities, with potential 10-15% corrections offset by year-end gains driven by AI-related spending.Benzinga · Jan 5, 2026

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP CongressGH Research announced presentation of long-term clinical data on GH001, a potential treatment for treatment-resistant depression, at the 38th Annual European College of Neuropsychopharmacology Congress in Amsterdam.GlobeNewswire Inc. · Oct 9, 2025

GH Research Announces Global Pivotal Program Plans and Further Development UpdatesGH Research submitted a complete response to FDA's clinical hold on GH001, with one remaining issue regarding respiratory tract histology in rats. The Phase 2b trial showed a 73% remission rate at 6 months for treatment-resistant depression, with no serious adverse events and promising treatment outcomes.GlobeNewswire Inc. · Jul 23, 2025

GH Research Submits Complete IND Hold Response to FDA Ahead of ScheduleGH Research PLC, a clinical-stage biopharmaceutical company, announced the submission of its complete response to the FDA regarding the clinical hold on its Investigational New Drug Application for GH001, its lead product candidate for treating treatment-resistant depression.GlobeNewswire Inc. · Jun 20, 2025

GH Research Reports First Quarter 2025 Financial Results and Provides Business UpdatesGH Research PLC reported positive results from a Phase 2b trial of its lead product candidate GH001 in patients with treatment-resistant depression, meeting the primary endpoint with a significant placebo-adjusted reduction in depression scores. The company also provided updates on its financial position and ongoing clinical development activities.GlobeNewswire Inc. · May 8, 2025

Postpartum Depression Pipeline Revealed in 2025 Forecast Report Featuring GH Research, Reunion Neuroscience, Lipocine, and Brii BiosciencesThe report provides an in-depth analysis of the Postpartum Depression (PPD) pipeline, showcasing insights into more than ten diverse companies and over ten pipeline drugs. It highlights innovative therapeutic candidates, including RE-104 by Reunion Neuroscience and GH001 by GH Research, and their potential impact on PPD treatment paradigms.GlobeNewswire Inc. · Mar 4, 2025

GH Research Reports Full Year 2024 Financial Results and Provides Business UpdatesGH Research PLC reported positive results from its Phase 2b clinical trial of GH001 in patients with treatment-resistant depression, with the primary endpoint met and a majority of patients achieving remission. The company also provided updates on its Phase 1 trial for a proprietary aerosol delivery device and its response to the IND hold on GH001. The company's cash position remains strong, with additional funding received from a public offering.GlobeNewswire Inc. · Feb 27, 2025

Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsightThe depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics.GlobeNewswire Inc. · Feb 25, 2025

GH Research Announces Pricing of $150 Million Public OfferingGH Research PLC, a clinical-stage biopharmaceutical company, announced the pricing of its $150 million public offering of 10,000,000 ordinary shares at $15.00 per share. The company is developing a novel treatment for treatment-resistant depression.GlobeNewswire Inc. · Feb 5, 2025

to start trading

GH

GHRSGH Research PLC Ordinary Shares

GHRS

Pay with—

Available Balance0.00

Your PositionYou don't own any GHRS yet.

Related Tickers

Earnings